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here is an extensive range of neurocognitive dis-
orders that are particularly prominent in older adults.These
include neurodegenerative diseases such as Alzheimer’s
disease (AD),frontal lobe dementia,Lewy-body dementia,
Parkinson’s disease;cerebrovascular disorders such as vas-
cular dementia; and more benign syndromes such as mild
cognitive impairment (MCI) and age-associated cognitive
decline (AACD). In recent years, there has been a bur-
geoning of research on therapeutic approaches to these dis-
orders. Changing demographics have underscored the
necessity to develop interventions for the remediation of
the cognitive impairment associated with pathological and
normal aging.
The prevalence of neurodegenerative diseases such as
dementia rises exponentially with increasing age.According
to recent United Nations projections, between the years
2000 and 2050 the number of individuals over 65 years of
age will exceed 1.1 billion worldwide. Based on these fig-
ures, the United Nations projects that the number of indi-
viduals with dementia in developed countries alone will
increase from 13.5 million to 36.7 million.
1 Utilizing these
demographics as well as current cost of care figures, Katz-
man and Fox
2 estimate that by 2050 the annual economic
toll of dementia will be $383.1 billion in the USA,$124.6 bil-
lion in Italy,$30.5 billion in France,and $11.2 billion in Eng-
land. The burden of this illness is such that investigators
stress not only the importance of finding a cure,but also the
necessity of intervening in the early stages of dementia to
prolong functionality and extend the time before institu-
tionalization.
The United Nations projects that the number of individ-
uals with dementia in developed countries alone will be
approximately 36.7 million by the year 2050. Interna-
tional recognition of the significant emotional and eco-
nomic burden of Alzheimer’s disease has been matched
by a dramatic increase in the development of pharma-
cological and nonpharmacological approaches to this ill-
ness in the past decade. Changing demographics have
underscored the necessity to develop similar approaches
for the remediation of the cognitive impairment associ-
ated with more benign syndromes, such as mild cogni-
tive impairment (MCI) and age-associated cognitive
decline (AACD). The present article aims to provide an
overview of the most current therapeutic approaches to
age-associated neurocognitive disorders. Additionally, it
discusses the conceptual and methodological issues that
surround the design, implementation, and interpreta-
tion of such approaches. 
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mentThese changing demographics will also impact the preva-
lence and incidence of MCI and AACD, since as many as
50% of individuals over age 65 currently fulfill the criteria
for at least one of these conditions. Such impairments in
cognition influence many day-to-day activities,from med-
ication adherence to productivity in the workplace and at
home.
3Additionally,extended longevity rates and increas-
ing numbers of older adults in our society suggest that
older workers may be required to continue working to
prevent financial overload on the retirement and pension
systems.
4,5 The elimination of mandatory retirement for
most occupations in the USA has made it possible for
older adults to stay in the workplace.Maintaining memory
and cognitive function is obviously important for older
adults,who want to—or are obliged to—continue working.
The end result of these social changes is that older adults
may not only want to live longer with better cognitive func-
tion, they may also need to.Additionally, preserving cog-
nitive function helps maintain aspects of living, such as
personal independence,that contribute to the good health
and overall quality of life in older adults.
In this article,we provide an overview of the current phar-
macological and nonpharmacological approaches to the
cognitive impairments associated with AD, MCI, and
AACD, since these represent the most prevalent neuro-
cognitive syndromes among older adults.Additionally,the
neuropathological mechanisms hypothesized to underlie
AD may also contribute to MCI and AACD.Indeed,many
investigators suggest there is a spectrum of pathophysio-
logical changes that accompany the normal aging process,
increase in severity to produce AACD and MCI, and, in
their most severe form, result in dementia. Such patholo-
gies include neurotransmitter deficiencies (particularly
cholinergic deficits),β -amyloid deposits,inflammation,neu-
roendocrine abnormalities, and immunological impair-
ment.Additionally,the genetic and environmental risk fac-
tors for the development of dementia also appear to be
associated with MCI and AACD.
6,7 Thus, the therapeutic
approaches developed to intervene with dementia have
informed,and will continue to inform,similar approaches
to MCI and AACD (Figures 1 and 2).
8
Alzheimer’s disease
AD is the most common form of dementia accounting
for 50% to 70% of all cases (Table I).Currently,there are
an estimated 4 million individuals with dementia in the
USA with more than 100 000 deaths annually, with
France,Italy,and England having close to 1 million cases
each,2 and in Greece there are 200 000 cases.9 AD is a
progressive, neurodegenerative disorder, characterized
neuropathologically by widespread neuronal loss, pres-
ence of neurofibrillary tangles, and deposits of β -amy-
loid in cerebral blood vessels and neuritic plaques.Since
the medial-temporal lobes, hippocampus, and associa-
tion cortex are significantly impacted,it is not surprising
that the primary symptom of AD is a decline in cognitive
functioning, which leads to marked impairment in daily
functioning. In particular, memory impairments, visu-
ospatial decline, language difficulties, and loss of execu-
tive function are central cognitive symptoms of this ill-
ness. Behavioral disturbances such as agitation and
hallucinations often accompany disease progression.
However, as emphasized by Cummings,10 despite the
presence of core clinical features,there is significant het-
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Selected abbreviations and acronyms
AACD age-associated cognitive decline
AAMI age-associated memory impairment 
A  amyloid  -peptide 
AChEI acetylcholinesterase inhibitor
AD Alzheimer’s disease 
ADAS-Cog Alzheimer’s Disease Assessment Scale–
Cognitive subscale
AMPA  -amino-3-hydroxy-5-methyl-4-isoxazole-
propionate 
APP amyloid precursor protein
ARCD age-related cognitive decline
CAT choline acetyltransferase
CGI-C Clinical Global Impressions Scale–Change 
ERT estrogen replacement therapy
IADL Instrumental Activities of Daily Living
MCI mild cognitive impairment
MMSE Mini-Mental State Examination
NMDA N-methyl-D-aspartate
NSAID nonsteroidal anti-inflammatory drug
Table I. Prevalence of dementia.
Alzheimer’s disease 65%–70% of dementia cases
Parkinson’s disease 8%–10% of dementia cases
Lewy body dementia 13%–15% of dementia cases
Vascular, mixed, 
5%–10% of dementia cases
and rare forms193
erogeneity in the cognitive and behavioral manifesta-
tions of AD.
The illness lasts approximately 7 to 10 years, with patients
requiring total care in the latter stages. Thus, AD places a
tremendous emotional and economic burden on both
patients and their caregivers. Beyond a cure, therapeutic
approaches that would alleviate the symptoms or delay pro-
gression could be of substantial benefit.When they modeled
the public health impact of delaying AD onset in the USA,
Brookmeyer and associates found that delaying onset by as
little as 6 months could reduce the numbers of AD patients
by half a million by 2050.
8,11 However, despite significant
progress in our characterization and understanding of AD,to
date there is no cure and researchers are still trying to more
fully understand its etiology.The pathophysiology of the ill-
ness is complex and, as many investigators suggest, likely
involves multiple, overlapping, and potentially interactive
pathways to neuronal damage.
10,12 However, in the past
decade there has been a significant increase in the develop-
ment of pharmacological approaches to this illness.
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Figure 1. Potential physiological path-
ways to Alzheimer’s disease.
APOE, apolipoprotein E; CSF,
cerebrospinal fluid; PET,
positron emission tomogra-
phy; fMRI, functional mag-
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Figure 2. Typical clinical course: current
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Current pharmacological approaches 
to Alzheimer’s disease
Neurobiological features of AD,including accumulation of
β -amyloid, neurotransmitter deficiencies, oxidation, and
hypothesized impairments in inflammatory and neuroen-
docrine mechanisms have informed the development of
current pharmacologic approaches. Table II lists the cen-
tral pathophysiological mechanisms hypothesized to lead
to AD and their associated pharmacological therapies.
Neurotransmitter deficiencies
Cholinergic deficits. To date, the best-developed treatment
for the symptoms of AD has been the attempt to remediate
the cholinergic deficit observed in this illness. On autopsy,
cholinergic markers in the cerebral cortex of AD patients
are reduced and these decreases correlate with cortical
pathology.
13,14 AD patients have been shown to have sub-
stantial neocortical deficits in choline acetyltransferase
(CAT), the enzyme responsible for the synthesis of acetyl-
choline (ACh),
15-17 reduced choline uptake and ACh
release,
18,19 and degeneration of cholinergic neurons of the
nucleus basalis of Meynert.
20 Other investigations have also
observed a significant reduction in the number of muscarinic
and nicotinic ACh receptors in AD brains.
21,22
Cholinergic deficits are well documented to be correlated
with the degree of cognitive impairment in AD patients,
and the neurotransmitter ACh has long been implicated in
learning and memory processes.
14,21 This has led to the
“cholinergic hypothesis”of AD,which holds that degener-
ation of cholinergic neurons in the basal forebrain and the
associated loss of cholinergic neurotransmission in the cere-
bral cortex and other areas contribute significantly to the
deterioration in cognitive function seen in patients with
AD.
The most successful approach to remediate the cholinergic
deficit in AD has been the use of acetylcholinesterase
inhibitors (AChEIs). AChEIs inhibit the enzyme, acetyl-
cholinesterase (AChE),which metabolizes ACh.Inhibiting
the action of the enzyme increases the concentration and
duration of action of ACh in synapses. AChEIs are cur-
rently the most successful drugs for enhancing ACh trans-
mission and appear more physiologically beneficial than
direct cholinoceptor activation. Three AChEIs, tacrine,
donepezil,and rivastigmine,have been approved by the US
Food and Drug Administration (FDA) and are currently
available on the market in over 60 countries.Galant-amine
has been approved in Europe and has been submitted for
approval by the FDA.
To assess the impact of pharmacological agents on cognition
and severity of illness,most clinical trials of AD utilize the
Alzheimer’s Disease Assessment Scale–Cognitive subscale
(ADAS-Cog), the Mini-Mental State Examination
(MMSE), and some assessment of clinical impression of
change,such as the Clinician’s Interview-Based Impression
of Change (CIBIC) scale.The ADAS-Cog is a psychomet-
ric scale that evaluates aspects of orientation, attention,
memory,language,reasoning,and praxis.
23,24The MMSE is a
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Table I. Pathophysiological mechanisms of Alzheimer’s disease and asso-
ciated therapeutic approaches.
HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A.
Neurotransmitter Tacrine
deficiencies Donepezil
Rivastigmine
Galantamine
Milacemide
Ampakines
Amyloid deposits β -Secretase inhibitors
γ -Secretase inhibitors
β -Amyloid vaccination
Inflammation Steroids
Nonsteroidal anti-inflammatory agents
Estrogen
Cyclooxygenase-2 inhibitors
Hydroxychloroquine
Colchicine
Oxidation α -Tocopherol (vitamin E)
Selegiline
Ginkgo biloba
Estrogen
Neuronal Piracetam
degeneration Pramiracetam
Idebenone
Cerebrolysin
Neuroendocrine Mifepristone
impairment
Cerebro- and  α -Tocopherol (vitamin E)
cardiovascular Selegiline
impairments  Ginkgo biloba
Estrogen
HMG-CoA reductase inhibitors
Calcium-channel-blocking agents195
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brief mental status examination designed to quantify global
cognitive status by assessing orientation,language,calcula-
tion, memory, and visuospatial reproduction.
25 While we
stress that there is significant heterogeneity,studies suggest
that the average rate of decline is 2 to 4 MMSE points per
annum,while the ADAS-Cog scores may increase on aver-
age by 3 to 10 points per year,depending upon the severity
of the illness.
26-28
Tacrine was the first AChEI to receive FDA approval 
for use in AD patients in 1993, but its use resulted in 
only modest improvements in cognition.
29-31 In addition,
tacrine has a lower bioavailability (amount of drug avail-
able in the body after absorption) than second-generation
cholinesterase inhibitors,such as donepezil hydrochloride.
32
It has also a poor side-effect profile that includes hepato-
toxicity.Currently 40% of AD patients in the USA are esti-
mated to be taking donepezil, which received FDA
approval in 1996.
33 Donepezil is a highly selective,noncom-
petitive, reversible AChEI.
34 It has a good side-effect pro-
file, which is not associated with hepatotoxicity, and sub-
stantially more patients are able to tolerate and achieve
therapeutic levels of donepezil than of tacrine.
35Also,there
is greater ease of administration with donepezil.The elim-
ination half-life is considerably longer for donepezil (70 to
80 h) in comparison to most other AChEIs (0.3 to 12 h).
A statistically significant improvement in cognition has
been observed in most randomized clinical trials of
donepezil,with an average improvement relative to placebo
of 2 and 3 points on the ADAS-Cog for 5 and 10 mg/day
doses,respectively.
34,36,37 However,this represents a relatively
modest improvement in cognition and the impact of this
degree of improvement on function is unclear.Indeed,some
donepezil trials did not find that patients perceived any
substantive improvement in function, despite objective
improvement in cognition and clinical impression scales.
Yet, a preliminary study utilizing pupil reaction to light
found that AD patients taking donepezil exhibited longer
latencies and higher amplitude of maximal response to light
than controls.
38
Rivastigmine is a selective, reversible inhibitor of both
AChE and butyrylcholinesterase (BuChE).
39,40 Double-
blind, placebo-controlled clinical trials lasting 6 months
found that rivastigmine resulted in statistically significant
differences in cognition in patients with mild-to-moderate
AD.
41 In particular, use of higher doses for 26 weeks
resulted in the most efficacious impact of rivastigmine on
cognition,with improvement of an average of 3 to 4 points
on the ADAS-Cog relative to placebo.
42,43 It appears that
rivastigmine requires a longer titration period to reach ther-
apeutic doses than donepezil.
44 However, Farlow et al
43
observed that patients originally treated with 6 to 12 mg/day
dose of rivastigmine for 52 weeks had only a 1.5-point
improvement on the ADAS-Cog relative to the placebo
group.
Additional AChEIs are in submission for approval in the
USA,including the second-generation galantamine,which
modulates nicotinic cholinergic activity, and metrifonate.
Findings from phase 2 and phase 3 randomized clinical tri-
als of galantamine observe an average of a 1.5-point
improvement on the ADAS-Cog relative to baseline in the
drug group,and an improvement of an average of 3 points
relative to placebo.
45-48 The development of other AChEIs,
such as phenserine, a derivative of the first-generation
physostigmine,is in progress.
Overall the AChEIs have produced only modest improve-
ments in the cognitive symptoms of AD patients, often
resulting more in stabilization than alleviation of cognitive
symptoms. Yet as data from clinical trials cumulate, it
appears that such stabilization may persist for up to 1 year
in a significant number of patients and longer-term studies
suggest that the progression of the disease is slowed by the
use of AChEIs.
34,49This may,in part,reflect the observation
that ACh stimulation appears to reduce the production of
β -amyloid through its action on the amyloid precursor pro-
tein (APP). Moreover, long-term use of tacrine has been
associated with preservation of nicotinic receptor binding as
measured by positron emission tomography (PET).
50 In
addition to the potential physiological benefits of long-term
use of AChEIs, pharmoeconomic analyses suggest that
there may be significant cost-savings if AChEI use prevents
AD decline for even 6 months.
51-53Thus,the refinement and
development of cholinesterase inhibitors continues, even
though AChEIs do not reverse or retard the neurodegen-
eration,which is the hallmark of this illness.
There are pharmacologic approaches to the cholinergic
deficiency, other than inhibition of AChE. For example,
muscarinic agonists to enhance the effect of ACh on nerve
cell receptors are in development. Since AChEIs depend
upon intact cholinergic neurons,direct-acting receptor ago-
nists that act at postsynaptic cholinergic sites have the
advantage of bypassing possibly degenerated presynaptic
terminals to enhance neuronal activity.
Other neurotransmitter deficiencies. AD-related deple-
tions in other neurotransmitters are also being consid-
ered for therapeutic approaches. Glutamatergic deficitshave been observed, with evidence indicating the loss of
glutamate markers in the brains of AD patients, particu-
larly in corticocortical connections.
54,55 Additionally, the
glutamate receptor,N-methyl-D-aspartate (NMDA),has
long been implicated in the acquisition of new memories
and has thus become a target for improving memory
function in AD. Memantine, an uncompetitive NMDA
antagonist,has been employed in European countries for
the treatment of dementia. However, while it appears to
have a positive impact on the Clinical Global Impression
Scale–Change (CGI-C) and measures of function, its
impact on cognition is less clear.
56 In general, the devel-
opment of glutamate agonists has been hampered by the
potential neurotoxic effects of overstimulating this sys-
tem.
57Thus,investigators have attempted indirect activa-
tion using glycine-like agonists,such as milacemide.Sev-
eral large, clinical trials of milacemide in AD patients
found no therapeutic benefit on the ADAS, MMSE, or
CGI-C.
58,59
Ampakines are also in development and aim to increase
activity of the glutamate receptor, α -amino-3-hydroxy-
5-methyl-4-isoxazolepropionate (AMPA). While the
ampakine Ampalex
® (1-[quinoxalin-6-ylcarbonyl]piperi-
dine, CX516) has been found to improve short-term
memory function in normal elderly adults,
60 there are as
yet no data on its use in AD patients.Another compound,
S12024 has been suggested to facilitate noradrenergic sys-
tems.
61,62 Initial clinical trials with this agent find improve-
ment on the MMSE in AD patients relative to placebo,
over a 12-week period.
63
AD-related deficiencies have also been observed in sero-
tonin and norepinephrine, but, although deficiencies in
these neurotransmitters are associated with cognitive
impairment, their enhancement is being considered pri-
marily to treat the behavioral and psychiatric symptoms
that can accompany AD.
 -Amyloid deposition
Many believe that more directly targeting the pathogenic
mechanisms involved in AD might result in more effica-
cious treatments.A central neuropathological feature of
AD is the accumulation of extracellular plaques, which
contain the amyloid β -peptide (Aβ ).In addition to direct
neurotoxic effects,Aβ appears to activate microglia pro-
ducing neurotoxins, cytokines, and free radicals.
64,65 Sev-
eral studies report that Aβ may compromise cholinergic
neuronal function independently of neurotoxicity sug-
gesting an association between Aβ deposits and choliner-
gic dysfunction in AD.
66,67Animal studies have found infu-
sion with Aβ to be associated with impairments in spatial
and working memory deficits.
68 Recently, there has been
increased focus on preventing the formation of Aβ , and
the amyloid cascade hypothesis offers a number of poten-
tial therapeutic targets. In particular, a central approach
has been the inhibition of the β - and γ -secretases that pro-
duce Aβ from the APP.As emphasized by Citron,
69 there is
no evidence for additional functions for Aβ ; however, β -
and γ -secretases are present in many different cells of the
body and potentially have substrates in addition to APP.
Thus,their inhibition may have associated toxicity effects.
There are also concerns that, by the time of diagnosis,
when the amyloid burden is sufficiently high in AD
patients, secretase inhibitors may only minimally impact
the existing symptoms.Clearance of existing plaques also
would be required for effective treatment.While inhibition
of the β - and γ -secretases may represent a particularly
effective approach to this disease,such treatments are still
in development.
A novel approach utilizing an immunological model,
observed amelioration of β -amyloid deposits in a mouse
model of AD following treatment with a vaccine com-
bining amyloid and substances that excite the immune
system.
70 The reduction in Aβ was observed not only in
younger mice, where vaccine treatment preceded onset,
but also in older animals where Aβ deposits were already
present. Phase 1 trials investigating this approach in AD
patients are currently nearing completion in the USA
and Europe.
Inflammation
AD lesions are also characterized by the presence of
inflammatory proteins. These include acute phase reac-
tants, inflammatory cytokines, and components of the
complement cascade.
71 The inflammatory proteins
observed in AD are produced by microglia and/or astro-
cytes.The parallel observation of an inverse relationship
between rheumatoid arthritis and AD led to the hypoth-
esis that anti-inflammatory agents reduce AD risk.
Recent literature suggests an association between nons-
teroidal anti-inflammatory drug (NSAID) use and
decreased AD risk, including prospective data from the
Baltimore Longitudinal Study of Aging. This has led to
the initiation of several clinical trials of anti-inflamma-
tory agents,many of which are still ongoing.
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As early as 1993, it was noted that patients with mild-to-
moderate AD treated with indomethacin,exhibited stable
cognitive performance relative to patients on placebo.
72
However, not all clinical trials with anti-inflammatory
agents have yielded positive findings.The Alzheimer’s Dis-
ease Cooperative Study (from the National Institute of
Aging [NIA]),
73 a multicenter, randomized, placebo-con-
trolled trial of low-dose steroid prednisone conducted in a
total of 138 subjects, observed no difference in cognitive
decline (assessed by the ADAS-Cog) between the pred-
nisone and placebo treatment groups in the primary intent-
to-treat analysis,or in a secondary analysis which included
completers only. On the basis of these findings, they con-
cluded that prednisone did not seem to be therapeutic for
AD patients.
Clinical trials of new anti-inflammatory agents,such as the
cyclooxygenase-2 (COX II), inhibitors are ongoing. Sev-
eral investigators have suggested that COX II inhibition
directly impacts neuronal function in addition to inflam-
matory microglia since COX II is present not only in
microglia but also in neurons.
74,75 Moreover,on the basis of
animal and cell studies, investigators suggest that COX II
activity may contribute to neurodegeneration in AD by
oxidative mechanisms.
76 Additional anti-inflammatory
drugs, including hydroxychloroquine and colchicine, are
being examined in clinical trials with AD patients.
Oxidation
Excess brain protein oxidation and decreased endogenous
antioxidant activity are well noted in both normal aging
and AD.
77Thus,reduction of oxidative stress has become a
target for the treatment of AD.Agents that protect against
oxidative damage, such as vitamin E and Ginkgo biloba
extract,are thought to reduce neuronal damage and poten-
tially slow the onset and/or progression of AD.An extensive
clinical trial of vitamin E and selegiline,a type B or selective
monoamine oxidase inhibitor, in AD patients found that
both compounds delayed the progression of nursing home
placement by approximately 6 months, thus precipitating
the widespread use of vitamin E. However, data on the
effects of such compounds on cognitive symptoms is more
limited.While preliminary studies indicate that both agents
are associated with improvements in cognition in AD
patients and asymptomatic older adults, lack of statistical
power limits generalization from these findings.
71
G biloba has also been employed in clinical trials with AD.
While the therapeutic activity of G biloba is complex and
likely involves the interaction and modulation of several
biological systems, evidence suggests that it is an effective
scavenger of both primary and secondary free radicals.
78,79
Findings from short-term clinical trials,which indicated that
G biloba might be effective in AD patients,
80-82 have been
supported by larger, longer-term investigations. At 52
weeks,patients receiving G biloba performed significantly
better than the placebo group on the ADAS-Cog,although
no differences were observed with respect to the CGI-C.
Additionally,26% of the patients achieved at least a 4-point
improvement on the ADAS-Cog, compared to 17% with
placebo (P=0.04).
83
Estrogen appears to act as both an antioxidant,protecting
brain cells from toxins by trapping free radicals, and an
anti-inflammatory agent by inhibiting brain cell deteriora-
tion.
84 Estrogen also is known to increase the level of CAT
in the basal forebrain, the frontal cortex, and most impor-
tantly in the CA1 layer of the hippocampus.Additionally,
many investigations suggest that estrogen plays a role in
promoting the growth and/or survival of neurons in areas
analogous to those most sensitive to degeneration in AD,
and animal studies indicate that estrogen maintains den-
dritic spine density in hippocampal pyramidal cells, regu-
lates receptors in the hippocampus,and stimulates synapse
formation.
84-86
Recent epidemiological studies suggest that estrogen use in
women may significantly delay AD onset and lower AD
risk. In a prospective case-control study, Kawas et al
87 uti-
lized records of 472 post- and perimenopausal women who
were followed for up to 16 years.Women taking estrogen
had a 54% reduction in risk for AD compared with women
who did not.Similarly,Tang
88 found that estrogen use during
menopause significantly delayed AD onset and lowered
AD risk.There is also a significant literature documenting a
positive effect of estrogen replacement therapy (ERT) on
the memory and cognition of nondemented individuals.
However, despite these findings, recognition of the non-
random basis by which estrogen is elected in the general
population requires that epidemiological evidence be sup-
ported by well-controlled randomized clinical trials.
To date,only a limited number of randomized clinical trials
of estrogen have been conducted in AD patients and these
have yielded mixed results. While some have found that
estrogen improved cognition in AD patients,
89 others did
not.In particular,two recent clinical trials found no bene-
fit of estrogen on cognitive function patients with mild-to-
moderate AD.Although one of these was only 16 weeks in
duration,
90 the year-long, multisite Alzheimer’s DiseasePharmacological aspects
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Cooperative Study found that ERT did not slow disease
progression and no differences between the treatment and
placebo group were observed with respect to cognitive or
functional measures.
91 Shaywitz and Shaywitz
92 suggest that,
in line with findings from animal studies,estrogen may be
most effective during initial use. For example, Mulnard et
al
91 found that estrogen-treated AD patients exhibited sig-
nificantly higher scores on the MMSE relative to placebo
after 8 weeks, although no difference between the groups
was observed after 1 year of treatment. While there are
not yet sufficient data to reach a definitive conclusion
regarding the merits of ERT for improving or stabilizing
the cognitive symptoms of AD patients, estrogen may be
effective in preventing or delaying the onset of dementia.
Neuronal degeneration
Neuronal degeneration is a central feature of AD,with cell
loss occurring throughout the brain,but most dramatically
in association cortex, medial temporal lobes, and hip-
pocampus.Thus, neurotrophic factors that might preserve
and stimulate neuronal development have received increas-
ing interest.Several investigators suggest that nerve growth
factor (NGF) might be valuable for the treatment of AD,
but its inability to cross the blood–brain barrier has posed
difficulties for this approach.
93 Research has focused on the
use of agents that appear to stimulate NGF production in
the brain,such as idebenone.One of the first double-blind,
multisite clinical trials to employ this agent in AD patients
found that patients treated with idebenone for 12 months
exhibited statistically significant,dose-dependent improve-
ment on the ADAS-Cog and its noncognitive counterpart
subscale, ADAS-Noncog, as well as on the CGI-C and
instrumental activities of daily living (IADL) subscales.
94
Further studies are required before the efficacy of
idebenone can be fully assessed.
Nootropics are suggested to be neural stimulants that
appear to augment neuronal function, including neuro-
transmitter release. However, clinical trials with two com-
mon nootropics,piracetam and pramiracetam have yielded
mixed results in AD patients.
95-97 As Flicker and Grimley-
Evans
98 conclude, the available evidence does not support
the use of piracetam in the treatment of people with
dementia because effects were found predominantly on
global impression of change, but not on any of the more
specific measures.
Recently,there has been increased focus on Cerebrolysin
®,
a porcine brain-derived peptide preparation, which has
been suggested to have neurotropic activity.
99 The results
of in vitro and in vivo studies suggest that Cerebrolysin
®
may reduce microglial activation,thus reducing the extent
of inflammation and accelerated neuronal death.
100 Two
recent placebo-controlled clinical trials found that,over a 4-
week period,Cerebrolysin
®-treated AD patients exhibited
significant improvement on the ADAS-Cog, CGI-C, and
the MMSE.
101,102Additionally,Ruther et al
102 found that the
improvements in cognition observed at 4 weeks appeared
to sustain in the drug group for up to 6 months posttreat-
ment. However, the long-term efficacy of this agent still
needs to be evaluated.
Neuroendocrine impairment
Impairment in the hypothalamic-pituitary-adrenal (HPA)
axis activity is another physiological mechanism proposed
to underlie the development of AD.
103-106 Hypercortisolemia
and reduced negative feedback inhibition of cortisol secre-
tion are noted concomitants of AD.
107-110 However, investi-
gations of the relationship between dementia severity and
cortisol levels have yielded mixed findings. While some
investigations observe a relationship between dementia
severity and/or progression,
111-115 others do not observe this
relationship between HPA dysfunction and either severity
or disease progression in AD.
116-118
However,variations in age of onset and stage of illness may
impact the relationship between hypercortisolemia and dis-
ease progression.Moreover,the nature of the relationship
between cortisol and cognitive decline in AD may be more
difficult to assess as the disease progresses.As many sug-
gest, the degenerative process of hippocampal damage in
AD patients may,with time,reduce the responsivity of this
area to elevations in glucocorticoids.Thus,many investiga-
tors argue that impairments in neuro-endocrine function
observed in AD reflect rather than cause the neuronal
degeneration in this illness.However,the observations of a
negative impact of elevated cortisol levels on cognition in
normal aging have led others to consider therapeutic
approaches to AD based upon this pathophysiological
mechanism.Currently,a clinical trial of AD patients,utiliz-
ing the glucocorticoid antagonist, mifepristone, is in
progress.
Cerebrovascular and cardiovascular impairments
While cerebrovascular deficiencies are typically associated
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gests that vascular factors may also contribute to the devel-
opment of AD.
119 Many recent studies have found arterial
hypertension to be associated with cognitive impair-
ment
120-123 and increased risk of AD has also been observed
in individuals with higher systolic-diastolic blood pressure
values.
124 Hofman et al
125 observed patients with AD to be
affected by more pronounced arteriosclerotic carotid
lesions,and atrial fibrillation was found to be more strongly
associated with AD (with cerebrovascular disease) than
with vascular dementia.
Some investigators have argued that vascular factors such
as arterial hypertension may have a direct role in the patho-
genesis of AD by increasing the production of β -amyloid.
Animal studies have found ischemia to result in increased
β -amyloid production in the hippocampus.
126 Moreover,the
observation of increased concentrations of senile plaques in
the brains of hypertensive, nondemented patients further
implicates the role of ischemia.
127 Investigators have started
to consider the use of antihypertensive agents as a potential
therapeutic approach to AD, but a recent study of such
agents in hypertensive,nondemented older adults indicated
a minimal positive impact upon cognitive impairment after
3 and 12 months of treatment.
128 However, the Syst-Eur
study found that use of a calcium-channel–blocking agent
reduced the incidence of AD in older adults with isolated
systolic hypertension.
129
In addition to the hypothesized association between
hypertension and the development of AD, the past few
years have seen a dramatic increase in the literature on
the potential link between cholesterol levels and the
development of AD. Several animal studies have found
hypercholesterolemia to accelerate AD amyloid pathol-
ogy,
130,131 and cholesterol was observed to modulate the
membrane disordering effects of β -amyloid in the hip-
pocampi of AD patients.
132The apolipoprotein E (APOE)
susceptibility gene for AD encodes for the APOE pro-
tein,which,among other things,is implicated in the trans-
port of plasma cholesterol. Recent studies have also
found increased serum cholesterol levels to be associated
with presence of the ε 4 allele in AD patients.
133-137 Some
studies did not observe this association,
138 and still others
suggest that the ε 4 allele is independently associated with
hypercholesterolemia and development of AD.
139
Overall, however, these findings have led investigators to
hypothesize a relationship among heart disease,cholesterol
levels, and the development of AD.
119,131 Wolozin et al
140
recently reported a decrease in the prevalence of AD to
be associated with the use of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, and a
placebo-controlled clinical trial of the HMG-CoA reduc-
tase inhibitor, Lipitor
® (atorvastatin calcium) is currently
ongoing in patients with mild-to-moderate AD.
It is interesting to note that estrogen has a positive impact
on lipoprotein levels and enhances cerebral blood flow,and
several investigators have proposed that these physiological
benefits of estrogen may account for its association with
reduced AD risk. Similarly, G biloba is noted to protect
against ischemic damage, and may thus have benefits on
cognition in AD patients.
Methodological and conceptual issues regarding 
therapeutic approaches to Alzheimer’s disease
While this is an exciting time for the development of phar-
macological approaches to AD,overall,the results of initial
randomized clinical trials of agents such as estrogen and
anti-inflammatory drugs have been somewhat disappoint-
ing. There are several important conceptual and method-
ological issues that significantly impact the interpretations
we can draw from the findings of many clinical trials in AD.
First, given the complexities of the pathophysiological
mechanisms that appear to be involved in the development
of AD,it is unlikely that treatments targeting any one neu-
ropathological pathway will be successful. Neuro-patho-
logical heterogeneity may impact drug mechanisms and
various pathophysiological mechanisms may interact to
produce AD. This has led several investigators to suggest
that combination treatments,or agents that simultaneously
impact different pathophysiological mechanisms,may have
greater efficacy than targeting only one specific pathway.
77,99
Schnieder et al
141 found that tacrine in combination with
estrogen was more efficacious than either agent alone in the
treatment of AD.Yet,Sano et al
142 did not find a combina-
tion of selegiline and vitamin E to be more efficacious than
either agent alone. However, it must be noted that these
two agents may impact similar pathophysiological mecha-
nisms.
Second, accumulating evidence suggests that individual
differences in genetic and other risk factors may also
affect drug response.Several studies have found a smaller
treatment response to tacrine and metrifonate in AD
patients positive for the ε 4 allele,although some observed
this effect only in women, suggesting the existence of a
gene–gender interaction.
93,143,144 However,others have sug-
gested that the impact of ε 4 may vary according to thera-
peutic approach, with studies of other compounds (eg,Pharmacological aspects
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the noradrenergic compound S12024) observing a better
treatment response in ε 4 carriers.
143,145 Many of these find-
ings are preliminary in nature,based on data from clinical
trials of short duration, with samples sizes that are too
small to yield large enough comparison groups of patients
with and without the ε 4 allele. Data from larger, long-
term clinical trials are required to more fully elucidate
the role of genetic and other risk factors in treatment
response, and it is interesting to note that in a large clin-
ical trial of galantamine, Wilcock et al
146 observed no
impact of the ε 4 allele on drug response.
Finally,variability in stage of illness,patient demograph-
ics,drug dose,duration of clinical trial,and other method-
ological issues also impact drug response.Many random-
ized clinical trials of newer pharmacological agents
include only highly selected populations,and more effec-
tiveness studies are required, which can provide “real
world”information.Typically,with respect to the AChEIs,
the most efficacious effects have been observed in
patients who have used higher doses for longer time peri-
ods. Indeed, with respect to agents such as estrogen and
anti-inflammatory drugs, where initial results have been
disappointing in AD,it is important to note that the short
duration of a clinical trial is in stark comparison to the
lengths of use found in the epidemiological studies that
have suggested their impact on AD. Long-term use of
such therapeutic approaches may prevent or slow AD
onset,but may be far less effective treatments during the
acute phases of the illness. This does not necessarily
diminish the potential positive impact of these
approaches on the illness itself, and many investigators
stress the importance of intervening in the preclinical and
early stages of AD where the antioxidant and anti-inflam-
matory agents may offer greater promise for preventing
and/or delaying rather than treating the cognitive symp-
toms associated with this illness.
Nonpharmacological approaches 
to Alzheimer’s disease
As emphasized by Reichman,
147 pharmacological ap-
proaches can be combined with behavioral and environ-
mental interventions that assist patients in maintaining
the highest possible level of function.Patients in the early
stages of dementia may benefit from support groups and
other constructive environments that provide informa-
tion and feedback on the cognitive and behavioral symp-
toms. Attempts to improve cognitive function in AD
patients through reality orientation, reminiscence, and
memory retraining have had some limited success.
148
Reality orientation was developed primarily to reduce
confusion and disorientation in dementia patients in insti-
tutionalized settings.A key feature of reality orientation
is to remind patients of who and where they are,provide
feedback on time of day, day of week, etc, comment on
and describe what is happening at a given moment in
time, and generally reinforce the patient’s awareness of
their environment. Recent studies have observed
improvements on the MMSE following sustained treat-
ment with reality orientation.
149,150 However,such changes
are often observed on the orientation components of the
MMSE, and reality orientation does not appear to sig-
nificantly impact behavioral functioning and, despite
improvement in cognition,improvements in IADL were
not observed in several studies.
150,151
There are a variety of memory training techniques that
have been employed with some success in nondemented
older adults, and we discuss these in detail below. These
techniques are typically not effective in patients with
dementia since their success relies upon utilization of many
of the information-processing systems,which are no longer
intact in dementia.However,prosthetic memory aids such
as diaries,memory wallets,and well-placed lists around the
house and garden have been found to be helpful,particu-
larly for early-stage patients who can benefit from the type
of mnemonic cueing such aids provide.
152,153 
Reminiscence therapy has also been postulated to be a
potentially effective therapy for patients with dementia
since studies suggest that memories for remote events
remain intact longer than other forms of memory.Remi-
niscence therapy aims to facilitate recall of past experi-
ences with the overall goal of enhancing well-being.Few
systematic studies of the effectiveness of reminiscence
therapy in dementia patients exist, but the limited data
available suggest that this technique may be more bene-
ficial to interpersonal communication than cognitive pro-
cessing.
154-156
Indeed,many of the aforementioned techniques can also
frustrate the dementia patient by underscoring the limi-
tations of their cognitive functioning.Behavioral therapy
approaches aimed at decreasing agitation, negative
thoughts, and depression, and improving self-care have
been quite successful. Additionally, studies suggest that
taking a behavioral management approach to improving
the mood and behavioral problems of AD patients may
also have benefit for cognitive symptoms.
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Although little empirical data exist,there is a clinical con-
sensus that modulating the environment may be very
helpful to the AD patient, in particular in ensuring that
their daily routine is consistent and their daily environ-
ment is not overstimulating. It has also been suggested
that providing feedback with respect to orientating AD
patients to time of day, place, and person in an informal
but consistent fashion may at the very least alleviate the
anxiety associated with loss of cognitive function.Still oth-
ers suggest that some AD patients may benefit from expo-
sure to the outside world through newspapers, radio, and
television. Mittelman et al
159 found that providing both
information and emotional support appeared to improve
quality of life indices and even delayed nursing home
placement. Most recently, the culmination of these views
has been reflected in an increased focus on the role of
occupational therapy in the management of dementia
symptoms. The COPE (Caregiver Options for Practical
Experience) study aims to further develop the role of
occupational therapists for working with dementia
patients.Deficits and strengths in a variety of sensorimo-
tor, cognitive, neuromusculoskeletal, and psychological
domains are assessed. Based upon this assessment the
occupational therapist then works with the patient and
their caregivers to design individualized approaches to
reducing the barriers to optimal functioning.
160
Future directions in Alzheimer’s disease
Despite the burgeoning research exploring a broad vari-
ety of pathophysiological approaches and pharmacologi-
cal compounds for the treatment of AD, observed
improvements in cognitive symptoms have been modest
at best, even with the most efficacious approaches. Sta-
tistical significance does not always translate into clinical
significance, and improvements on such measures as the
ADAS-Cog or MMSE are often not associated with sim-
ilar improvements on clinical rating scales, measures of
IADL, or patient or caregiver ratings of function. Even
when improvement or stabilization of cognitive function
occurs, such benefits invariably do not sustain. While
approaches such as reduction of β -amyloid may yield
more efficacious treatments in the future, current
approaches are limited. As Skoog and Gustafson
161
emphasize,the evidence suggests that secondary preven-
tion is particularly important with respect to AD. Sec-
ondary prevention occurs when an illness is detected
early, in the preclinical stage, at which point treatment
can be implemented to prevent it from progressing to the
clinical phase of the illness.Recognition that agents such
as estrogen may protect against rather than treat AD has
also fueled the emphasis on the secondary prevention of
AD.This view is reflected in an increased focus not only
on the early identification of preclinical AD, but also on
the classification and remediation of the cognitive and
memory problems that occur with age.
Cognitive change in normal aging
Age-related changes in cognition among the healthy are
well documented. Several psychometric measures of
attention,memory,and reasoning abilities,as well as those
emphasizing speed,display particularly robust age-related
declines.Less pronounced declines in measures of knowl-
edge, such as vocabulary, are observed with age.
162-164
Although much of this information is based on cross-sec-
tional studies, longitudinal sequences from the Seattle
Longitudinal Study,among others,confirm the existence
of age-related decline on several measures of cognitive
performance.
7,165-168“Data on rates of aging … suggest that
a rapid rise to peak performance in the third and fourth
decades of life is followed by a ‘continuous decline’ which
is slight over the fifth and sixth decades and thereafter
rapidly accelerates” (Rabbitt, 1990).
169 While investiga-
tors may disagree as to the ages at which decline in cog-
nitive function occurs,there is a consensus in the aging lit-
erature that cognition does not decline uniformly across
the life span.
One of the clearest findings to emerge from the field of
cognitive aging is that older adults are unable to recall as
much as younger adults from long-term memory.
162,170,171
Memory difficulties worsen with advancing age and are a
major aging complaint.
172-174 Many older adults find their
memory and cognitive impairments debilitating on a daily
basis and find that they interfere with many of their daily
activities. It was the recognition of age-associated cogni-
tive decline that appeared to go beyond that typically
associated with normal aging that led to the classifica-
tion of such problems as AACD and MCI.
Defining normal vs MCI vs pathological aging
Over the past 20 years there have been several proposals
regarding how best to characterize the spectrum of memory
function in nondemented older adults. Ferris and Kluger
175
have reviewed in detail the following proposed characteri-zations: mild cognitive impairment (MCI), age-associated
memory impairment (AAMI), and age-related cognitive
decline (ARCD). While initial descriptions of MCI sug-
gested that some individuals likely decline on a variety of
cognitive domains, more recently, MCI has come to refer
more specifically to presence of memory impairment greater
than expected for an individual’s age, with general cogni-
tive function preserved and no other neurological deficit
present that is consistent with dementia.
6,174As many as 12%
of MCI cases per year have been found to progress to
dementia over the course of 4 years.
6 AAMI is a concept
developed by a National Institute of Mental Health
(NIMH) workgroup
175,176 attempting to label the memory
loss associated with normal aging.The criterion developed
by this group for diagnosing AAMI was scores “at least 1
standard deviation below the mean established for young
adults” on a normed, standardized test of recent memory.
After much debate,ARCD became the Diagnostic and Sta-
tistical Manual of Mental Disorders–4th edition (DSM-IV)
variant of AAMI and was designed to include both memory
and other cognitive changes associated with aging.To ensure
that the ARCD label did not imply pathology, the word
“deficit”was eliminated from its definition and ARCD was
included in the “Other Conditions” section of the DSM.A
major issue left unresolved was development of specific
diagnostic criteria for the application of the term ARCD.
In contrast to AAMI, age-associated cognitive decline
(AACD) measures gradual decline in cognitive function,
and uses norms for similarly aged and educated subjects
to assess whether an individual fits the criteria for this clas-
sification. Unlike the concept of ARCD, there are specific
criteria for AACD,and cognitive domains other than mem-
ory,including attention,problem solving,and language abil-
ities can be involved.The classification for AACD requires
a documented decline in a single cognitive function beyond
that expected for similar age and education levels,but with-
out evidence of dementia.
177
While MCI is typically viewed as representing a preclinical
phase of AD,recently,investigators have recently suggested
that a greater number of individuals classified as AACD
convert to dementia, than individuals with MCI.
178 In par-
ticular, these investigators question the necessary involve-
ment of a memory impairment in order to be classified as
having cognitive decline,arguing that this is too restrictive
given the heterogeneity among presenting cognitive symp-
toms in AD patients. Additionally, the prevalence of
AACD,AAMI,and MCI is such that,given the most liberal
projections,there is no way that all individuals so classified
will,in fact,develop dementia.Yet,many older adults have
memory and other cognitive impairments that they find
impact their day-to-day functioning,and there is an increas-
ing demand among older adults for therapeutic interven-
tions to remediate such cognitive deficits.This demand has
been matched by an increased focus among clinicians,
researchers, and pharmaceutical industries on developing
pharmacological approaches for the palliative treatment of
the cognitive impairments associated with such entities as
AACD and MCI.
Perhaps the most controversial issue in separating out nor-
mal aging deficits,from AACD and MCI,from dementia is
the concept of coexisting pathology. While the cognitive
deficits associated with such classifications do not reflect
degenerative pathological processes,it is unlikely that they
do not reflect the physiological changes in brain function
that are commonly associated with aging. These changes
include many of the pathophysiological mechanisms that,in
a more severe form, underlie dementia, including neuro-
transmitter deficiencies, inflammation, and oxidation. As
Sherwin
179 points out in her review of pharmacological
treatment options for MCI,there has been less emphasis on
such approaches for the remediation of cognitive problems
in nondemented older adults than in AD.Yet ironically, a
significant number of clinical trials have been conducted
to assess the impact of a variety of pharmacological agents
on cognition in normal aging, AAMI, AACD, and MCI.
Many of the therapeutic approaches to AD have been uti-
lized in such populations,less often to assess the benefits for
this population than as the first step in assessing their safety
and efficacy for use in AD patients.
Pharmacological approaches in AACD,
MCI,and normal aging
Neurotransmitter deficiencies
Cholinergic deficits. Numerous studies suggest that central
cholinergic activity declines with age.While profound cell
loss from the cortex itself has generally not been observed,
loss of subcortical cholinergic neurons may be associated
with normal aging.
13 Neurons located in the subcortical
basal forebrain region provide cholinergic innervation to
the hippocampus and neocortex. Degeneration of these
neurons likely contributes to cognitive impairment. An
age-related decrease in the presynaptic activity of CAT
has been reported in humans.
180 CAT is considered a
marker of cholinergic neurons; thus its decline with age
Pharmacological aspects
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Since postsynaptic muscarinic receptor binding also
decreases with age,
181 it appears that both presynaptic and
postsynaptic cholinergic degeneration are involved in the
process of normal aging.
Baxter et al
182 demonstrated in rodents that most of the
age-related changes in cholinergic markers were already
present at ages at which behavioral impairment was not
yet maximal. A postmortem study in humans, however,
somewhat challenges this finding: cholinergic deficits,
measured as activity of the cholinergic enzymes CAT and
AChE, were apparent in elderly individuals with severe
dementia, but not in individuals with moderate, mild,
questionable,or no dementia.
183
However, administration of the cholinergic antagonist
scopolamine in humans has been found to impair the
encoding of information into long-term memory and to
impact other cognitive processes.
22,184,185 Since a cholinergic
antagonist is associated with impairments in memory and
cognition, cholinergic enhancers, especially AChEIs, may
ameliorate such impairments.
186-188 Cholinergic enhancers
(for example,arecoline,a muscarinic agonist,and choline,
a precursor of ACh) have been tested on effects on per-
formance of memory tasks in healthy volunteers after
administration of the cholinergic antagonist methscopo-
lamine. Both drugs reversed scopolamine-induced
impairment of serial learning.
189 Poor baseline performers
proved to be more vulnerable to both the enhancing effect
of the cholinergic agonist and precursor and the impair-
ment after cholinergic antagonist than good performers.
A number of studies of AChEIs in humans of varying
ages suggest a broad range of effects on memory and
attentional processes. Early studies administering the
cholinesterase inhibitor physostigmine to aged humans
190
observed significant improvement in performance on
long-term and recent memory and picture recognition
tasks, further supporting a cholinergic role in memory
decline with age. Recent studies with newer compounds
have found similar effects.
191-193
In a recent cerebral blood flow study with healthy human
volunteers (age range 22 to 68 years),cholinergic enhance-
ment with physostigmine was associated with improved
working memory efficiency,as indicated by faster reaction
times and reduced activation of cortical regions associated
with working memory.
194 Similarly,in a more recent investi-
gation using functional magnetic resonance imaging
(fMRI),Furey et al
195 found that physostigmine resulted in
enhanced neural processing in visual cortical areas during a
visual working memory task,particularly during encoding.
They conclude that augmenting cholinergic function may
improve working memory by enhancing the selectivity of
perceptual processing during encoding. Cholinergic drugs
have also been associated with improvements on measures
of visual attentional function, leading some reviewers to
suggest that part of the benefit of cholinergic drugs upon
memory performance may be mediated through the atten-
tional components involved in working memory.
13,21,196
The impact of AChEIs on a range of memory and other
cognitive processes suggests that they may represent a
valuable approach to enhancing cognitive function in
older adults asymptomatic for dementia.An NIA-funded
clinical trial of donepezil is ongoing in individuals classi-
fied as MCI.
Other neurotransmitter deficiencies. While there are lim-
ited data on the impact of the AChEIs in older adults,there
have been several studies examining the impact of modu-
lating glutamate receptors in this population. As men-
tioned, the neurotransmitter glutamate has been impli-
cated in cognitive function, and has been suggested to
decrease with increased age. Direct activation of NMDA
receptors has proved problematic, and several investiga-
tions have attempted indirect stimulation via glycine-like
agonists such as milacemide. While milacemide has not
been found to be therapeutic in AD, studies in nonde-
mented,older adults found that it improved working mem-
ory, verbal and visual memory, and attention.
197-199 How-
ever, in a randomized clinical trial of the glycine agonist,
cycloserine, no significant impact on cognition was
observed in subjects classified as AAMI.
62
In a clinical trial in older subjects,using ampakines,which
target AMPA receptors, Lynch et al
60 observed a dose-
dependent improvement in delayed recall performance.
Additional clinical trials with these compounds are in
progress.
As mentioned, S12024 facilitates noradrenergic and vaso-
pressinergic systems and preliminary findings indicate that
this compound enhances cognition in older adults with
AACD.
61,62,200
Inflammation and oxidation
In addition to the documented reduced risk of AD among
asymptomatic older adults using NSAIDs, recent studies
have investigated the relationship between use of anti-
inflammatory agents and cognitive function in this popula-
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203tion. In a study of 13 153 individuals, between 48 and 67
years of age, who regularly utilized NSAIDs or asprin, no
associations between NSAID use and any of the cognitive
tests were observed, although a modest association was
observed between aspirin use and better performance on
delayed recall and verbal fluency tests.
201 Yet others
observed no positive impact of prescription NSAID use
on cognitive function in community-dwelling older adults.
202
However, as emphasized by Pasinetti,
76 daily doses of up
to 1200 mg of NSAIDs such as ibuprofen are analgesic but
not anti-inflammatory,and it typically requires daily doses
of 2400 mg for a systemic anti-inflammatory effect. It is
interesting to note that in an investigation of the impact of
chronic NSAID use on cognitive decline in older adults,
Rozzini et al
203 found a positive association between chronic
NSAID use and reduction in cognitive decline over 3 years,
as measured by the Short Portable Mental Status Ques-
tionnaire.As Karplus and Saag
204 point out,large-scale,ran-
domized,controlled trials using NSAIDs in this population
are needed before it is clear whether the known risks of
NSAIDs are outweighed by their potential long-term ben-
efits on cognition.
There have been several investigations of the impact of G
biloba on cognitive function in adults asymptomatic for
dementia. Several of these studies found that G biloba
appeared to improve speed of processing and memory
function,particularly on measures of working memory.
205-207
However, these studies were typically short in duration,
ranging from 6 hours to 12 weeks, and included middle-
aged rather than older adults.Several large-scale,multisite,
randomized clinical trials of G biloba in older adults are
ongoing and their results should further clarify the rela-
tionship between this agent and cognitive performance in
this population.
The influence of estrogen on cognition and memory in nor-
mal aging has also received considerable recent attention.
208-214
One of the most consistent findings to emerge from the
above literature links estrogen to the maintenance of mem-
ory function in aging women. Several studies found that
estrogen significantly improved performance on tasks of
both the immediate and delayed recall of verbal and non-
verbal material.
213-217 While several observational studies
have shown that estrogen administration has a positive
effect on attention span,concentration,and memory func-
tion,others have not observed an association between ERT
and cognitive function.
218-220 Methodological differences
among these investigations,including variation in the age of
subjects and the cognitive tests employed,may account for
the mixed results. In particular, there is often inconsistent
use of estrogen over time in postmenopausal women,which
may impact the outcomes from such observational investi-
gations. However, recent evidence from imaging studies
lends further support for a positive benefit of estrogen on
cognitive functioning. In cortical regions typically
hypometabolic in AD, Eberling et al
221 found that older
women who had never taken estrogen exhibited metabolic
ratios intermediate to those of AD patients and women on
ERT.Similarly,a longitudinal assessment of regional cere-
bral blood flow changes observed increased flow over time
in estrogen users compared with nonusers, particularly in
the hippocampus and temporal lobes.
222
Since the decision to take ERT may be impacted by edu-
cation and socioeconomic variables, randomized clinical
trials are needed to systematically address the merits of
estrogen for cognitive processing in older women.To date,
there have been a limited number of randomized clinical
trials of estrogen use in healthy individuals,with the major-
ity short-term in duration and often investigating younger
adults.
215,223 Data from large,long-term,randomized clinical
trials in this population are required before we can ade-
quately assess the long-term benefits of estrogen use on
cognition as well as its role in AD prevention.
Neuronal degeneration 
Several clinical trials with nootropics, such as piracetam,
have been conducted in older adults,and a significant pos-
itive impact of piracetam on both memory and attentional
functions was observed.
224-226Additionally,two studies have
investigated the affect of 4.8 g/day of piracetam on the dri-
ving ability of elderly adults exhibiting deficits in psy-
chomotor speed at baseline.While some investigators found
that treatment with piracetam reduced the numbers of
errors committed in real traffic, still others observed no
benefit of piracetam on driving performance.
62,227 The few
studies conducted with pramiracetam in this population
have also observed improvements in memory performance
relative to placebo.
228,229
Nonpharmacological treatments for normal aging
Memory training
Studies from several groups including our own have docu-
mented the efficacy of providing cognitive training aimed at
instructing older adults to use mnemonics for practical
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230-234 How-
ever, some have criticized such interventions because the
effects demonstrated have often been modest and short-
term.
235 Furthermore, only a few studies have examined
whether the benefits of memory training programs persist
for longer periods and these have yielded mixed results.
236-238
Additionally,it is unclear whether or not subjects continue
to employ the mnemonic technique acquired and whether
this reported use of the mnemonic affects memory 
function.Several investigators found that at follow-up sub-
jects had ceased to apply the mnemonic techniques
acquired.
236-238Yet,in our recent work,we followed 112 com-
munity-dwelling older adults,4 to 5 years after training and
found that 40% of them stated that they employed the
training at follow-up. These participants exhibited better
memory performance at follow-up than they had prior to
the start of their training. However, those subjects who
exhibited the best memory performance at baseline bene-
fited most from the memory training.
239 This suggests that
alternative interventions may need to be considered for
elderly adults who may be particularly vulnerable to mem-
ory decline with age and who thus do not benefit as effec-
tively from such mnemonic training.
For example,one novel approach to cognitive impairment
in older adults has been the attempt to combine pharma-
cological and memory training. Israel et al
240 conducted a
double-blind randomized trial of a total of 135 older adults
with AAMI. Two intervention methods, piracetam and
memory training, were assessed in combination.The com-
bination of piracetam and memory training resulted in sig-
nificantly better performance on measures of immediate
and global recall than observed with memory training com-
bined with placebo.Additionally,the combined pharmaco-
logical and training approach appeared to be most effective
in patients whose baseline performance on memory tests
was lowest.
Stress reduction
Increases in stressful events accompany increased age,
106,241
and several investigators have suggested that life stressors
contribute to ARCD. A recent investigation of this rela-
tionship found that cognitive decline with age appeared to
occur regardless of stressful life events, with the exception
of the death of a spouse or child, which was found to be
associated with greater cognitive decline.
241 However,
Creasey et al
242 observed that prisoners of war appeared to
have a significantly greater percentage of cognitive disor-
ders.Most recently,investigators have suggested that a his-
tory of posttraumatic stress disorder (PTSD) may be a risk
factor for the development of AD.
235,243 Although findings
from these studies are suggestive,there are methodological
weaknesses relating to lack of appropriate control subjects
and variation in the measures employed.In addition,none
of the above studies included measures of cortisol response
or other measures of HPA activity.
The literature suggests that stress may have an interactive
effect with HPA changes with age,resulting in the acceler-
ation of hippocampal atrophy,memory decline,and/or the
development of AD.
105,106,244 Many investigations have
observed increased levels of glucocorticoids in aging ani-
mals and humans.
106 The observation in animals that pro-
longed exposure to high plasma cortisol levels causes irre-
versible hippocampal damage led to speculations that
increased levels of corticosteroids are neurotoxic and that
long-term hypercortisolemia may accelerate cognitive
decline and the dementia process.
103,110 Longitudinal stud-
ies indicate that,while some older adults exhibit decreases
in cortisol levels over time, the greater majority exhibit
increases in cortisol over time.
245-247These increases in corti-
sol also appear to impact cognitive decline. Several recent
studies have found increased cortisol levels in nondemented
older adults to be associated with reduced hippocampal
volume and with decline in memory function.
245,248-251 It has
also been suggested that increased levels of the adrenal
steroid dehydroepiandrosterone (DHEA) protect against
any negative impact of stress, since studies suggest that
DHEA may enhance hippocampal function and improve
memory.Berkman et al
252 found high levels of DHEA to be
associated with higher cognitive performance in older
adults.However,other investigators observed no such rela-
tionship.
253,254 However, Kalmijn
248 found that the ratio of
free cortisol to DHEAS was significantly related to decline
on the MMSE over 1 to 2 years in a sample of healthy
elderly adults,leading investigators to speculate that a pro-
gressive age-related increase of the cortisol/DHEA ratio
may induce cortisol-mediated hippocampal lesions.Overall,
as suggested by Lupien et al,
250 impaired HPA activity may
be an important factor contributing to the genesis of mem-
ory deficits with age.
However, what is not clear from the literature is whether
chronic levels of recent psychosocial stressors are associated
with abnormal or increasing cortisol response in this popu-
lation,or how sustained levels of chronic psychosocial stress
may impact cortisol response over time in this population.
To date,there have been no studies of the long-term impact
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HPA axis activity, and cognitive decline in older adults. If
stress-associated abnormalities in cortisol response impact
hippocampal function and cognitive decline with age,then
this could have significant implications for the use of both
pharmacological and nonpharmacological approaches,such
as systematic stress reduction programs, for reducing this
response and thus alleviating cognitive decline.
Physical and cognitive activity
Age-related cognitive changes have long been linked to
health status.
255 In particular, illnesses such as diabetes,
hypertension, and cardiovascular deficits have been doc-
umented to be associated with decline on a broad range of
cognitive domains.
256-259 Individual differences in genetic
and environmental factors may interact with these ill-
nesses to impact cognitive function. For example, pres-
ence of the APOE ε 4 allele has been observed to increase
the risk of cognitive decline associated with arteriosclero-
sis,peripheral vascular disease,and diabetes mellitus.
260
However, while specific illnesses are well documented to
be associated with increased risk of cognitive decline in
older adults,the findings regarding health practices in this
population have been more ambiguous. Investigators of
the Sydney Older Persons Study examined whether health
habits were associated with cognitive functioning,demen-
tia, or AD in subjects aged 75 years or older.
261 At a 3-
year follow-up of 327 subjects involving clinical and cog-
nitive assessments, few significant associations were
observed between health habits and cognitive perfor-
mance.No associations were found with dementia or AD.
It is important to note that this analysis was based upon
self-reports of health habits rather than clinical assess-
ment of health status.Exercise and other physical activity
interventions have been shown to improve cognition in
older adults.In a randomized trial,Hassmen et al
262 found
that participants randomly assigned to an exercise group
(regular walking,three times a week for 3 months) exhib-
ited significantly better performance than controls on
complex cognitive tasks following the intervention.
Most recently, there has been an increased focus on the
role of cognitive activity and social engagement in main-
taining good cognitive function with age.Investigators of
the Victoria Longitudinal Study examined the hypothesis
that maintaining intellectual engagement through partic-
ipation in everyday activities buffers individuals against
cognitive decline in later life.
263 In a longitudinal study,
they examined the relationships among changes in lifestyle
variables and cognition.Decreases in intellectually related
activities were associated with decline in cognitive func-
tioning. However, as the investigators point out, while
their findings suggest that intellectually engaging activities
buffer against cognitive decline, an alternative explana-
tion is that the pursuit of intellectually active lives may
be confounded with educational level and socioeconomic
status, such that individuals pursuing such activities
throughout their life span continue to do so until cognitive
decline in old age limits these activities.
Still other investigators have suggested that social engage-
ment, defined as the maintenance of many social con-
nections and a high level of participation in social activi-
ties, guards against cognitive decline in elderly persons.
Bassuk et al
264 examined the relationship between a global
social disengagement scale, which included information
on presence of a spouse, monthly visual contact with
three or more relatives or friends, yearly nonvisual con-
tact with relatives or friends, attendance at religious ser-
vices,group membership,and regular social activities,and
cognitive performance as assessed by the Short Portable
Mental Status Questionnaire. These investigators found
that individuals with minimal social ties were at increased
risk for cognitive decline, and suggested that social dis-
engagement may be a risk factor for cognitive impair-
ment among elderly persons.As with intellectual activi-
ties, it is difficult to know whether lower levels of social
engagement reflect rather than precipitate cognitive
decline.Further studies are required to more fully address
these issues.
Current issues
Many of the same concerns that impact our interpreta-
tion of clinical trials in AD,also limit our interpretation of
similar approaches in nondemented populations.As is the
case of AD research,individual differences in genetic and
other risk factors,such as presence of the ε 4 allele or years
of education, have been documented to impact cognitive
decline with age.
7 Such individual differences may also
impact response to pharmacological and nonpharmaco-
logical approaches to the remediation of cognitive aging.
In addition to the significant heterogeneity among older
adults, there is increasing concern regarding the hetero-
geneity among cognitive assessments typically employed
in these populations. While many individuals argue that
tests such as the ADAS-Cog and MMSE are not suffi-
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least these measures are consistently employed in such
clinical trials, forming a constant yardstick of measure-
ment,and thus facilitating comparison across trials.How-
ever, in asymptomatic older adults, one of the significant
confounders in this literature is the extreme variability in
the cognitive measures employed across studies. Studies
vary not only with respect to the cognitive domains
assessed but also with respect to the measures employed
to assess the same cognitive domain.Additionally,several
investigators suggest that available neuropsychological
measures, traditionally developed with clinical popula-
tions in mind,may not be sufficiently sensitive to decline,
particularly in high functioning and/or younger elderly
adults.
265 Such concerns also raise issues regarding the
assessment and subsequent criteria for such entities as
AACD and MCI.
A recent investigation has attempted to evaluate the pre-
dictive validity and temporal stability of the diagnostic
criteria for MCI. In a longitudinal population study,
Ritchie et al
178 found that, using current classification cri-
teria in the general population, the prevalence of MCI
was estimated to be 3.2% and AACD 19.3%. MCI was a
poor predictor of dementia within a 3-year period,with an
11.1% conversion rate.Subjects with MCI also constituted
an unstable group,with almost all subjects changing cate-
gory each year. On the other hand, subjects classified as
AACD appeared to constitute a more stable group,with a
28.6% rate of conversion to dementia over 3 years. The
investigators suggest that the current diagnostic criteria
may need to be modified in order to increase their capac-
ity to detect preclinical dementia.
Another concern with respect to cognitive decline in aging
populations asymptomatic for dementia is how much
decline is of clinical significance.Definitions of what con-
stitutes a significantly low score on a psychometric mea-
sure vary considerably. In the recent handbook on the
neuropsychology of aging,La Rue and Swanda
166 propose
the following yardstick for at least mild deficit, namely
performance ≥1 to 1.5 standard deviations below that of
same age peers constitutes a significantly lower score.Yet
other investigators argue that cognitive decline is best
assessed longitudinally, relative to an individual’s base-
line performance.Further,while performance on IADL in
AD patients tends to be associated with performance on
such mental status examinations as the ADAS-Cog and
MMSE, there is only a limited literature attempting to
link age-related changes in cognitive performance to func-
tional activities. The Observed Tasks of Daily Living
(OTDL) is one measure that attempts to assess the ability
of older adults to solve practical problems with respect to
various activities of daily living.
266,267 Diehl et al
266 tested a
hierarchical model in which speed of processing and mem-
ory span are basic processing resources and different
everyday problems require the activation of different con-
stellations of cognitive abilities. Their outcome measure
was the OTDL and they found that neither memory nor
speed had significant direct effects on older adults’ OTDL
performance.Indirect effects through the ability factors of
fluid and crystallized intelligence were significant.Overall
however, much work remains to be done to more fully
assess the impact of cognitive decline on complex tasks of
daily living.
Future directions in normal aging
It is clear from the literature that there is an increasing
demand to remediate or at least forestall the cognitive
deficits associated with AACD, MCI, and even normal
aging.While not all older adults will develop dementia,
this population appears to be less tolerant of the
declines in cognitive function that accompany normal
aging. The evidence suggests that there is a growing
emphasis on pharmacological approaches to prevent or
reverse cognitive decline in these populations, not only
with a view to preventing the onset of dementia, but
also in order to enhance day to day cognitive function-
ing in older adults.These approaches will be accompa-
nied by increased research on cognitive test measure-
ment and sensitivity,and the concomitant refinement of
the criteria for such entities as AACD and MCI. Most
recently,we have seen the supplementation of cognitive
testing with other measurement approaches,in particu-
lar brain imaging.Several studies have observed reduc-
tions in regional brain activation in older adults at
increased risk for dementia, although no differences in
neuropsychological test performance were observed.
268,269
The inclusion of brain imaging measures may increase
our sensitivity for detecting cognitive decline and pre-
clinical AD. Pharmacological approaches to cognitive
aging will continue to result in an increased emphasis on
defining the clinical and functional significance of cog-
nitive decline in these populations. Finally, future
research will likely integrate pharmacological and non-
pharmacological approaches for the remediation of age-
associated cognitive impairment. ❑
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Aproximaciones terapéuticas a los trastornos
neurocognitivos asociados con la edad
Las Naciones Unidas proyectan que el número
de individuos con demencia sólo en los países
desarrollados será de aproximadamente 36,7
millones para el año 2050. El reconocimiento
internacional del significado emocional y de la
carga económica de la enfermedad de Alzheimer
se ha acompañado de un incremento dramático
en el desarrollo de propuestas farmacológicas y
no farmacológicas para esta enfermedad en la
última década. Los cambios demográficos han
subrayado la necesidad de desarrollar estrategias
similares para remediar el deterioro cognitivo
asociado con síndromes más benignos, tales como
el deterioro cognitivo leve (DCL) y la declinación
cognitiva asociada con la edad (DCAE). El pre-
sente artículo apunta a proveer una visión acerca
de las propuestas terapéuticas más actuales para
los trastornos neurocognitivos asociados con la
edad. Adicionalmente se discuten temas concep-
tuales y metodológicos que se relacionan con el
diseño, implementación e interpretación de tales
propuestas.
Approches thérapeutiques des troubles
neurocognitifs liés à l’âge
Les Nations unies estiment que le nombre de per-
sonnes atteintes de démence sera de l’ordre de
36,7 millions en 2050 en ce qui concerne les seuls
pays développés. La prise de conscience interna-
tionale de la charge économique et affective
considérable que représente la maladie d’Alzhei-
mer s’est accompagnée d’une augmentation
spectaculaire du développement des recherches
pharmacologiques et non pharmacologiques de
cette maladie dans les dix dernières années. L’évo-
lution des données démographiques a mis en évi-
dence la nécessité de développer des approches
similaires pour remédier au déficit cognitif asso-
cié à des syndromes moins graves, tels que le défi-
cit cognitif bénin (MCI) et le déclin cognitif lié à
l’âge (AACD). Cet article a pour but de fournir
une vue d’ensemble des approches thérapeu-
tiques les plus courantes ayant trait aux troubles
neurocognitifs liés à l’âge. En outre, il examine les
problèmes méthodologiques et conceptuels sou-
levés par la conception, la réalisation, et l’inter-
prétation de telles approches. 
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